Sun Pharma Advanced Research Wins Rs 27.51 Crore CENVAT Credit Refund Dispute, Tribunal Dismisses Revenue's Appeal:

Sun Pharma Advanced Research Company Limited has informed the stock exchanges about the development concerning its business. The company has disclosed that the tribunal, in a recent hearing, has ruled in its favour by sustaining an Order-in-Appeal dated April 27, 2018.

The tribunal has ruled that the company is entitled to a refund of accumulated CENVAT credit along with consequential interest, where applicable, for an amount of Rs 2751 Lakhs. Accordingly, the final decision has been announced in the company's favour, and the Tax Department's appeal has been dismissed.

The company further clarified that as the final decision has been announced in its favour, it does not expect any impact on its financial position.

The aforementioned disclosure has been made by Sun Pharma Advanced Research Company Limited under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, vide an Intimation dated October 04, 2026, addressed to the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE).

Refer to the official intimation for complete information.